酒井 洋 さかい ひろし 先生

来歴等

略歴

1980年 自治医科大学医学部 卒業
1996年 埼玉県立がんセンター呼吸器科 医長
2002年 埼玉県立がんセンター呼吸器科 副部長
2008年 埼玉県立がんセンター呼吸器科 科長兼部長
2008年 埼玉県立がんセンター呼吸器内科（科名変更） 科長兼部長

論文

• Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med.DOI: 10.1056/NEJMoa1910231 September 28, 2019.

  Matthew D. Hellmann, M.D., Luis Paz-Ares, M.D., Ph.D., Reyes Bernabe Caro, M.D., Ph.D., Bogdan Zurawski, M.D., Ph.D., Sang-We Kim, M.D., Ph.D., Enric Carcereny Costa, M.D., Keunchil Park, M.D., Ph.D., Aurelia Alexandru, M.D., Lorena Lupinacci, M.D., Emmanuel de la Mora Jimenez, M.D., Hiroshi Sakai, M.D., Istvan Albert, M.D., Alain Vergnenegre, M.D., Solange Peters, M.D., Ph.D., Konstantinos Syrigos, M.D., Ph.D., Fabrice Barlesi, M.D., Ph.D., Martin Reck, M.D., Ph.D., Hossein Borghaei, D.O., Julie R. Brahmer, M.D., Kenneth J. O'Byrne, M.D., William J. Geese, Ph.D., Prabhu Bhagavatheeswaran, Ph.D., Sridhar K. Rabindran, Ph.D., Ravi S. Kasinathan, Ph.D., Faith E. Nathan, M.D., and Suresh S. Ramalingam, M.D.

• Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis.Cancer Science, 2019. https://doi.org/10.1111/cas.14120.

  Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L. Vowler, Tetsuya Mitsudomi.

• Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies. Cancer Science, 8:5183-5193, 2019. https://doi.org/10.1002/cam4.2411

  Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, et al.

• Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). Clin Lung Cancer. 2019 Jul 31. pii: S1525-7304(19)30209-8. doi: 10.1016/j.cllc.2019.07.005. [Epub ahead of print]

  Nishio M, Sugawara S, Atagi S, Akamatsu H, Sakai H, Okamoto I, Takayama K, Hayashi H, Nakagawa Y, Kawakami T.

• First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer. Cancer Treat Res Commun. 2019;18:100113. doi: 10.1016

  Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, Nokihara H, Satouchi M, Nakagawa S, Tahata T, Nakagawa K.

• KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small‐cell lung cancer. Cancer Science Volume110, 1012-1020, 2019

  Makoto Nishio, Toshiaki Takahashi, Hiroshige Yoshioka, Kazuhiko Nakagawa, Tatsuro Fukuhara, Kazuhiko Yamada, Masao Ichiki, Hiroshi Tanaka, Takashi Seto, Hiroshi Sakai, Kazuo Kasahara, Miyako Satouchi, Shi Rong Han, Kazuo Noguchi, Takashi Shimamoto, Terufumi Kato.

• A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy. Japanese Journal of Clinical Oncology, Volume 49, Issue 2, 1 February 2019

  Akihiko Osaki Kenichi Inoue Hiroshi Sakai Kazuhiko Yamada Koichi Minato Fumiyoshi Ohyanagi Yutaka Tokuda Norihiko Ikeda Hiroshi Kagamu Kaoru Kubota Tomohide Tamura Toshiaki Saeki.

• Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opin Pharmacother. 2018, 19:1049-1056.

  Yukio Hosomi, Chiharu Tanai, Kiyotaka Yoh, Yasushi Goto, Hiroshi Sakai, Terufumi Kato, Takayuki Kaburagi, Makoto Nishio, Young Hak Kim, Akira Inoue, Yoshinori Hasegawa, Hiroshi Isobe, Yoshio Tomizawa, Yoshiaki Mori, Koichi Minato, Kazuhiko Yamada, Yasuo Ohashi and Hideo Kunitoh.

• Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. Esmoopen-2016-000108 Published 25 January 2017

  Makoto Nishio, Toyoaki Hida, Shinji Atagi, Hiroshi Sakai, Kazuhiko Nakagawa, Toshiaki Takahashi, Naoyuki Nogami, Hideo Saka, Mitsuhiro Takenoyama, Makoto Maemondo, Yuichiro Ohe, Hiroshi Nokihara, Tomonori Hirashima, Hiroshi Tanaka, Shiro Fujita, Koji Takeda, Koichi Goto, Miyako Satouchi, Hiroshi Isobe, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura.

• Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non- small cell lung cancer in patients previously treated with platinum-based chemotherapy. Invest New Drugs
DOI 10.1007/s10637-017-0435-2: Published online 30 January 2017.

  Yuichi Tambo, Yukio Hosomi, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Yasutsuna Sasaki, et al.

• Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 13 (2017) . doi:10.1016/S1470-2045(17)30230-9

  Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto, Hideyuki Harada, Hiroshi Nokihara, Hideo Saka, Makoto Nishio, Hiroyasu Kaneda, Koichi Takayama, Osamu Ishimoto, Koji Takeda, Hiroshige Yoshioka, Motoko Tachihara, Hiroshi Sakai, Koichi Goto, Nobuyuki Yamamoto.

• Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer. 2017 Mar;105:23-30. doi: 10.1016/j.lungcan.2017.01.007. Epub 2017 Jan 17.

  Katakami N, Hida T, Nokihara H, Imamura F, Sakai H, Atagi S, Nishio M, Kashii T, Satouchi M, Helwig C, Watanabe M, Tamura T.

• Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci (2017) doi: 10.1111/cas.13225.

  Toyoaki Hida, Makoto Nishio, Naoyuki Nogami, Yuichiro Ohe, Hiroshi Nokihara, Hiroshi Sakai, Miyako Satouchi, Kazuhiko Nakagawa, Mitsuhiro Takenoyama, Hiroshi Isobe, Shiro Fujita, Hiroshi Tanaka,Koichi Minato, Toshiaki Takahashi, Makoto Maemondo, Koji Takeda, Hideo Saka, Koichi Goto, Shinji Atagi, Tomonori Hirashima, Naoki Sumiyoshi and Tomohide Tamura.

• Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study　DOI: 10.1136/esmoopen-2017-000214 Published 14 September 2017

  Yasushi Goto, Chiharu Tanai, Kiyotaka Yoh, Yukio Hosomi, Hiroshi Sakai, Terufumi Kato, Takayuki Kaburagi, Makoto Nishio, Young Hak Kim, Akira Inoue, Yoshinori Hasegawa, Hiroshi Isobe, Yoshio Tomizawa, Yoshiaki Mori, Koichi Minato, Kazuhiko Yamada, Yasuo Ohashi, Hideo Kunitoh

• North East Japan Study Group. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.Lung Cancer Volume 99, September 2016, Pages 131-136.

  Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K

• Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. ESMO Open, 2018 vol 3(1) pp e000288-7, Published 29 January 2018.

  Hidehito Horinouchi, Kaoru Kubota, Akihiko Miyanaga, Shinji Nakamichi, Masahiro Seike, Akihiko Gemma, Yuki Yamane, Futoshi Kurimoto, Hiroshi Sakai, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Tomohide Tamura, Yuichiro Ohe.

• Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Supportive Care in Cancer pp 1-9, First online: 29 April 2016

  Kaoru Kubota, Mitsue Saito, Kenjiro Aogi, Ikuo Sekine, Hirohisa Yoshizawa, Yasuhiro Yanagita, Hiroshi Sakai, Kenichi Inoue, Chiyoe Kitagawa, Takashi Ogura.

• Case report of two patients having successful surgery for lung cancer after treatment for Grade 2 radiation pneumonitis. Annals of Medicine and Surgery Volume 5, February 2016, Pages 1-4

  Yuki Nakajima, Hirohiko Akiyama, Hiroyasu Kinoshita, Maiko Ataria, Mitsuro Fukuhara, Yoshihiro Saitoc, Hiroshi Sakai, Hidetaka Uramoto.

• Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer, Published online: December 22, 2016.

  Terufumi Kato, Noriyuki Masuda, Yoichi Nakanishi, Masashi Takahashi, Toyoaki Hida, Hiroshi Sakai, Shinji Atagi, Shiro Fujita, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Yoshinobu Namba, Tomohide Tamura.

著書

• 【共著】恩田直美・酒井　洋.レジデントノート.化学療法による悪心・嘔吐のマネージメント.羊土社.2017年

• 【共著】恩田直美・酒井　洋.肺癌診療Q&A.術後再発性の治療方針.中外医学社.2017年

• 【共著】水谷英明・酒井　洋.あたらしい肺癌現場診断学.TKI耐性さあどうする.南江堂.2018年

• 【共著】水谷英明・酒井　洋.あたらしい肺癌現場診断学.PDL1陽性さあどうする.南江堂.2018年

• 【共著】恩田直美・酒井　洋.肺癌化学療法改訂2版.オンコロジークリニカルガイド　今後の治療の展望.南山堂.2019年

• 【共著】須藤淳子・酒井　洋.EBM呼吸器疾患の治療.代謝拮抗薬における最新のエビデンスは？.中外医学社.2016年

• 【共著】酒井　洋.分子呼吸器病.新薬の最新の話題　ニボルマブ（非小細胞肺癌）.先端医学社.2016年